Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101973 | 0.80 | — | — | |
| Ethane SCHEMBL27676633 | 0.78 | CRBN (0.55) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL17849896 | 0.72 | TOP2A (0.51) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL18766091 | 0.72 | CRBN (0.35) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL16480076 | 0.70 | CRBN (0.58) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL18561777 | 0.70 | — | — | |
| SCHEMBL11683393 | 0.70 | — | — | |
| SCHEMBL905165 | 0.68 | — | — | |
| SCHEMBL12394131 | 0.67 | — | — | |
| SCHEMBL17948964 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-9371283-B2 | Polycyclic tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | CRBN 2461/4885TOP2A 122/4885TOP2B 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.